Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion (NCT03132779) | Clinical Trial Compass
UnknownPhase 1
Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion
34 participantsStarted 2017-05-01
Plain-language summary
Evaluating the effect of intralipid on the natural killer cells
Who can participate
Age range18 Years – 38 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* All women icluded having recurrent spontaneous abortions equal or more than twice.
* Alittle women having increased NKCELLS activity.
Exclusion Criteria:
* Any other diseases causing miscarriage as autoimmune (lupus erythematosus or antiphospholipid antibodies syndrome )or endocrinopathy (diabetes mellitus, thyroid disorders and hyperprolactinaemia)or thrombophilia (factor v leiden mutation, protein c or s deficiency, prothrombin G20210A mutation, antithrombin III deficiency ) or abnormal karyotyping to one or both of parents or previous history of hormonal contraception or intrauterine device usage at last 3 months or any contraindications for intralipid usage.
What they're measuring
1
Change in NK cells activity after injection of intralipid